Drugs / YOLT-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07193615 | Jun 2025 → Jan 2027 expected | alpha 1-antitrypsin deficiency | RenJi Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YOLT-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07193615 ↗ |
| Route | Intravenous | “The IP is administered intravenously at the predetermined dose” NCT07193615 ↗ |